Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$141.75 USD

141.75
681,591

+2.42 (1.74%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 80.43% and 19.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Glaukos (GKOS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos (GKOS) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

by Zacks Equity Research

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 21.79% and 55.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Glaukos in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

Glaukos (GKOS) Up 13.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

Glaukos (GKOS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of -25.71% and -0.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Down 45.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

What's in the Offing for LabCorp's (LH) Earnings in Q4?

by Zacks Equity Research

With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

What's in the Cards for DaVita (DVA) This Earnings Season?

by Zacks Equity Research

DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.

BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings

by Zacks Equity Research

BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.

Why Is Glaukos (GKOS) Up 1.2% Since Last Earnings Report?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up

by Zacks Equity Research

Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 41.18% and 3.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Glaukos (GKOS) Up 2.3% Since Last Earnings Report?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised

by Zacks Equity Research

Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of -10.00% and 4.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.